KB-1452
JNJ79635322-CD3-hIgG1
Background of JNJ79635322-CD3-hIgG1
JNJ-79635322 is a novel trispecific antibody that simultaneously targets three different antigens: BCMA (B-cell maturation antigen), GPRC5D and CD3. By binding to BCMA and GPRC5D on the surface of multiple myeloma cells, as well as CD3 on T cells, JNJ-79635322 brings the T cells into close proximity with the myeloma cells. This cross-linking of the three targets (BCMA, GPRC5D, and CD3) triggers the activation and cytotoxic function of the T cells, leading to the killing of the BCMA and GPRC5D-expressing myeloma cells. JNJ-79635322-CD3-hIgG1 is a monoclonal antibody that binds to the CD3 protein.
Specifications
| Catalog Number | KB-1452 |
|---|---|
| Antibody Name | JNJ79635322-CD3-hIgG1 |
| Isotype | Human IgG1, kappa |
| Target | CD3E&CD3D |
| Species Reactivity | Human |
| Host Cell Line | EXPI CHO |
| Purification Method | Affinity purified |
| Concentration | >2 mg/mL |
| Formulation | 50 mM sodium citrate,150mM NaCl,pH5.5 |
| Purity | >95% by SDS-PAGE and SEC-HPLC |
| Validation | ELISA |
| Endotoxin Level | <0.2 EU/mg as determined by the LAL method |
| Sterility | 0.2μm filtered |
| Storage | It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
| Stability | Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity. |
Characterization
Application
References
- Bahlis NJ, Tomasson MH, Mohty M, et al.. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma Naïve to B-Cell Maturation Antigen (BCMA)-directed therapies: results from cohort a of the magnetismm-3 study. Blood 2022; 140:391–393.
- Touzeau C, Krishnan AY, Moreau P, et al.. Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents. J Clin Oncol 2022; 40:8013–18013.